|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC-1) has been recognized as biomarker of pancreatic cancer.
|
30202003 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
|
29721179 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-GPC1 mAb also inhibited tumor growth of GPC1 positive ESCC patients derived tumor xenograft models.
|
28445969 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
|
28232049 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
|
28232049 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of glypican-1 is differentially altered among different types of malignancies, suggesting a possible role in the tumorigenesis and biological behavior of these neoplasms.
|
25046223 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Remarkably, the enhanced expression of Notum, a conserved feedback antagonist of Wnt, was observed in tumors along with alterations in Glypican-1 and Glypican-3 levels.
|
26517809 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Changes in proteoglycan core proteins differ depending on their location; those located intracellularly or in the extracellular matrix show very similar alteration patterns, while those located on the cell surface vary greatly depending on the nature of the tumor: glypicans 1, 3, 6 and betaglycan are affected in the non-metastatic tumors, whereas in the metastatic, only glypican-1 and syndecan-1 are modified, the latter showing opposing alterations in levels of RNA and of protein, suggesting post-transcriptional regulation in these tumors.
|
26482785 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Levels of GPC1(+) crExos correlate with tumour burden and the survival of pre- and post-surgical patients.
|
26106858 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GPC1(+) crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreatic cancer to facilitate possible curative surgical therapy.
|
26106858 |
2015 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
GPC1(+) crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreatic cancer to facilitate possible curative surgical therapy.
|
26106858 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that miR-96-5p/-182-5p as good markers for PC; miR-96-5p, rather than -182-5p, inhibits GPC1 to suppress proliferation of PC cells.
|
24736782 |
2014 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that miR-96-5p/-182-5p as good markers for PC; miR-96-5p, rather than -182-5p, inhibits GPC1 to suppress proliferation of PC cells.
|
24736782 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GPC1 expression leads to a significant downregulation of the tumor suppressors pRb, Cip/Kip cyclin-dependent kinase inhibitors (CKIs), and CDH1, and upregulation of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (CDK2), Skp2, and Cdt1.
|
24019070 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of the importance of members of the TGF-beta family in pancreatic cancer, in the present study, the role of GPC1 in TGF-beta, BMP and activin signaling was analyzed.
|
17016645 |
2006 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of the importance of members of the TGF-beta family in pancreatic cancer, in the present study, the role of GPC1 in TGF-beta, BMP and activin signaling was analyzed.
|
17016645 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a good correlation between glypican-1 and syndecan-1 expression in the tumors.
|
11454708 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, glypican-1 antisense-expressing PANC-1 cells exhibited a significantly reduced ability to form tumors in nude mice in comparison with parental and sham-transfected PANC-1 cells.
|
10505759 |
1999 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was reported that glypican-1 is strongly expressed in human pancreatic cancer, and that it may play an essential role in regulating growth-factor responsiveness in pancreatic carcinoma cells.
|
10505759 |
1999 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was reported that glypican-1 is strongly expressed in human pancreatic cancer, and that it may play an essential role in regulating growth-factor responsiveness in pancreatic carcinoma cells.
|
10505759 |
1999 |
|
Hepatomegaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Hypopituitarism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hypothyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ophthalmoplegia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Pruritus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|